title: [Results of docetaxel therapy in patients with relapsed ovarian cancer].
abstract: Successful treatment of relapsed ovarian cancer has not been solved. Docetaxel, being one of the medicines of special interest in Hungary from 2002, has been ranked with the other well known treatment forms. In this study the authors evaluated the results of the docetaxel-carboplatin combination treatment in two oncological centers.
  
  
  METHODS
  Sixteen patients with relapsed ovarian cancer, premedicated with steroids, were given docetaxel-carboplatin chemotherapy at a dose of 75 mg/m2 and AUC 5 in 94 courses at the Gynecological Dept., National Institute of Oncology and Oncotherapeutic Clinic of Szeged University. Median of courses was 6 (range: 2 to 15).
  
  
  RESULTS
  CR was found in 1, PR in 4 and PD in 5 patients. Six patients showed stable disease. There was no need for dose reduction. The authors observed no extreme side effects (this evaluation does not contain the data of a patient who refused chemotherapy because of the development of hypersensitivity reaction). Almost all patients developed reversible alopecia. The probability of freedom from progression dropped to 50% 5 months after the beginning of treatment.
  
  
  CONCLUSIONS
  Docetaxel has expanded the chemotherapeutic arsenal in relapsed ovarian cancer. Our results are in harmony with those reported in the literature on other drugs or combination treatments. Further trials are required to improve the effectiveness of chemotherapy.
authors.affiliation: Nôgyógyászati Osztály, Országos Onkológiai Intézet, 1122 Budapest, Ráth György u.7-9, Hungary. lehoczky@oncol.hu
authors.forename: Ottó
authors.initials: O
authors.lastname: Lehoczky
authors.forename: László
authors.initials: L
authors.lastname: Thurzó
authors.forename: Andrea
authors.initials: A
authors.lastname: Bagaméri
authors.forename: Zsuzsanna
authors.initials: Z
authors.lastname: Sárosi
authors.forename: János
authors.initials: J
authors.lastname: Udvary
authors.forename: Tamás
authors.initials: T
authors.lastname: Pulay
mesh_terms: D000328:Adult; D000368:Aged; D000505:Alopecia / Q000139:chemically induced; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage; D000077143:Docetaxel; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D016190:Carboplatin